



Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Nucala (mepolizumab)**. Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: [1-866-331-2104](tel:1-866-331-2104)]. If you have any questions or concerns, please call [1-866-331-2103](tel:1-866-331-2103). **Requests will not be considered unless all sections are complete.**

KP-MAS Formulary can be found at: [Pharmacy](#) | [Community Provider Portal](#) | [Kaiser Permanente](#)

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Prescriber Information

Is the prescriber a pulmonologist, allergist, or rheumatologist? No Yes

If consulted with a specialist, specialist name and specialty: _____

Prescriber Name: _____ Specialty: _____ NPI: _____

Prescriber Address: _____

Prescriber Phone #: _____ Prescriber Fax #: _____

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone # _____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____
Sig: _____

Drug 2: Name/Strength/Formulation: _____
Sig: _____

5– Diagnosis/Clinical Criteria

Clinical Criteria:

1. Member has diagnosis of uncontrolled moderate to severe asthma defined as any of the following:
 - a. ≥ 2 exacerbations in the past 12 months requiring systemic corticosteroids for more than 3 days
 - b. ≥ 1 asthma exacerbation(s) leading to hospitalization in the past 12 months
 - c. Dependence on daily oral corticosteroids (OCS) for asthma control
 - d. Poor symptom control (ACT score less than 20) No Yes
2. AND member has uncontrolled asthma despite good adherence (at least 75% over the past 3 months) to a regimen containing: a high dose inhaled corticosteroid, long-acting beta 2 agonist, AND long-acting muscarinic antagonist, and consideration given to use of a leukotriene receptor antagonist
 No Yes
3. AND member is ≥ 6 years,
 No Yes
4. AND Nucala will NOT be used with Fasenra (benralizumab), Cinqair (reslizumab), Xolair (omalizumab), Dupixent (dupilumab), or Tezspire (tezepelumab-ekko),
 No Yes
5. AND Nucala is being used for one of the following indications:
 - a. Eosinophilic asthma (non-OCS dependent) with serum eosinophil count ≥ 300 cells/microliter in the past 12 months,
 - b. OR eosinophilic asthma (OCS-dependent) with serum eosinophil count ≥ 150 cells/microliter in the past 12 months,
 - c. OR eosinophilic granulomatosis with polyangiitis in patients ≥ 18 years No Yes
6. AND if using for eosinophilic asthma and aged 6-12 years, documented treatment failure, contraindication or inadequate response to Dupixent,
 No Yes
7. AND if using for eosinophilic asthma and aged ≥ 12 years, documented treatment failure, contraindication, or inadequate response to Fasenra and Dupixent
 No Yes

For continuation of therapy, please respond to additional questions below:

1. Does the member have documentation of positive clinical response to Nucala therapy in combination therapy?
 No Yes
2. AND has the member continued to be under the care of a specialist?
 No Yes

7 – Prescriber Sign-Off

Additional Information –

1. **Please submit chart notes/medical records for the patient that are applicable to this request.**
2. **If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:**

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:	Date:
------------------------------	--------------

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility